Aytu BioPharma(AYTU) - 2027 Q1 - Quarterly Results
Exhibit 99.1 Aytu BioPharma Reports Fiscal 2027 First Quarter Operational and Financial Results "Our first quarter performance was driven by growth in EXXUA, with net revenue increasing to $4.9 million and total prescriptions growing to 4,400 for the quarter, up approximately 33% sequentially from the June quarter," commented Josh Disbrow, Chief Executive Officer of Aytu. "We look forward to continuing to support patients living with major depressive disorder." ● Net revenue increased 6.9% to $14.8 million ...